Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS

References

• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236.
   PubMed Web of Science ®Google Scholar
• Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Chan JL, Kar S, Vanky E, et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. Am J Obstet Gynecol. 2017;217:189.e1–189.e8.
   Web of Science ®Google Scholar
• Ganie MA, Marwaha RK, Dhingra A, et al. Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar. Gynecol Endocrinol. 2016;32(7):566–570.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–1174.
   PubMed Web of Science ®Google Scholar
• Cibula D, Skrha J, Hill M, et al. Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(12):5821–5825.
   PubMed Web of Science ®Google Scholar
• Barberri RL, Makris A, Randall RW, et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62:904–910.
   PubMed Web of Science ®Google Scholar
• Shabir I, Ganie MA, Zargar MA, et al. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J Endocr Metab. 2014;18:364–369.
   PubMedGoogle Scholar
• Ganie MA, Dhingra A, Nisar S, et al. Oral glucose tolerance test significantly impacts the prevalence of abnormal glucose tolerance among Indian women with polycystic ovary syndrome: lessons from a large database of two tertiary care centers on the Indian subcontinent. Fertil Steril. 2016;105(1):194–201.
   PubMed Web of Science ®Google Scholar
• Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS ONE. 2017;12(11):e0186136.
   PubMed Web of Science ®Google Scholar
• Marciniak A, Nawrocka Rutkowska J, Brodowska A, et al. Cardiovascular system diseases in patients with polycystic ovary syndrome – the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 2016;23(4):537–541.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M. Management of endocrine disease: morbidity in polycystic ovary syndrome. Eur J Endocrinol. 2017;176:R53–R65.
   PubMed Web of Science ®Google Scholar
• Orio F, Muscogiuri G, Nese C, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:214–219.
   PubMed Web of Science ®Google Scholar
• Brennan L, Teede H, Skouteris H, et al. Lifestyle and behavioral management of polycystic ovary syndrome. J Womens Health (Larchmt). 2017;26(8):836–848.
   PubMed Web of Science ®Google Scholar
• Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome—an update. Fundam Clin Pharmacol. 2012;26(1):54–62.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5:CD003053.
   PubMed Web of Science ®Google Scholar
• Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004;89:4655.
   Web of Science ®Google Scholar
• Castello MF, Eden JA. A systemic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003;79:1–13.
   PubMed Web of Science ®Google Scholar
• Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98(9):3599–3607.
   PubMed Web of Science ®Google Scholar
• Du Q, Yang S, Wang YJ, et al. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2012;29(9):763–774.
   PubMed Web of Science ®Google Scholar
• Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother. 2012;46(2):282–289.
   PubMed Web of Science ®Google Scholar
• Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia. 2015;58(10):2238–2246.
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab. 2005;90(1):60–65.
   PubMed Web of Science ®Google Scholar
• Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2006;126(1):93–98.
   PubMed Web of Science ®Google Scholar
• Jensterle M, Sebestjen M, Janez A, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159(4):399–406.
   PubMed Web of Science ®Google Scholar
• Liao L, Tian YJ, Zhao JJ, et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J. 2011;124(5):714–718.
   PubMed Web of Science ®Google Scholar
• Cataldo NA, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2006;21(1):109–120.
   PubMed Web of Science ®Google Scholar
• Batista JG, Soares JM Jr., Maganhin CC, et al. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics. 2012;67(3):283–287.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   Web of Science ®Google Scholar
• Morley LC, Tang T, Yasmin E, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017;11:CD003053.
   PubMed Web of Science ®Google Scholar
• Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611–618.
   PubMed Web of Science ®Google Scholar
• Sabbadin C, Andrisani A, Zermiani M, et al. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Invest. 2016;39(9):1015–1021.
   PubMed Web of Science ®Google Scholar
• Nanjan MJ, Mohammed M, Prashantha Kumar BR, et al. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018;77:548–567.
   PubMed Web of Science ®Google Scholar